Claims
- 1. A method for preventing or treating risk factors for cardiovascular disease in an individual, comprising:
administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.
- 2. The method of claim 1, wherein said risk factors for cardiovascular disease are selected from the group consisting of obesity, the metabolic syndrome, diabetes, vascular disorders and renal disorders.
- 3. The method of claim 1, wherein said estradiol metabolite is selected from the group consisting of 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol and 4-hydroxyestradiol.
- 4. The method of claim 1, wherein said composition comprises a controlled release formulation of said composition.
- 5. The method of claim 1, wherein said composition comprises a prodrug of said estradiol metabolite.
- 6. A method for the prevention or treatment of obesity in an individual, comprising:
administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.
- 7. The method of claim 6, wherein said estradiol metabolite is selected from the group consisting of 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol and 4-hydroxyestradiol.
- 8. The method of claim 6, wherein said composition comprises a controlled release formulation of said composition.
- 9. The method of claim 6, wherein said composition comprises a prodrug of said estradiol metabolite.
- 10. A method for the prevention or treatment of the metabolic syndrome in an individual, comprising:
administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.
- 11. The method of claim 10, wherein said estradiol metabolite is selected from the group consisting of 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol and 4-hydroxyestradiol.
- 12. The method of claim 10, wherein said composition comprises a controlled release formulation of said composition.
- 13. The method of claim 10, wherein said composition comprises a prodrug of said estradiol metabolite.
- 14. A method for the prevention or treatment of diabetes mellitus in an individual, comprising:
administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.
- 15. The method of claim 14, wherein said estradiol metabolite is selected from the group consisting of 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol and 4-hydroxyestradiol.
- 16. The method of claim 14, wherein said composition comprises a controlled release formulation of said composition.
- 17. The method of claim 14, wherein said composition comprises a prodrug of said estradiol metabolite.
- 18. A method for the prevention or treatment of renal disease in an individual, comprising:
administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.
- 19. The method of claim 18, wherein said estradiol metabolite is selected from the group consisting of 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol and 4-hydroxyestradiol.
- 20. The method of claim 18, wherein said composition comprises a controlled release formulation of said composition.
- 21. The method of claim 18, wherein said composition comprises a prodrug of said estradiol metabolite.
- 22. A method for the prevention or treatment of insulin resistance in an individual, comprising:
administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.
- 23. The method of claim 22, wherein said estradiol metabolite is selected from the group consisting of 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol and 4-hydroxyestradiol.
- 24. The method of claim 22, wherein said composition comprises a controlled release formulation of said composition.
- 25. The method of claim 22, wherein said composition comprises a prodrug of said estradiol metabolite.
- 26. A method for the prevention or treatment of vascular endothelial dysfunction in an individual, comprising:
administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.
- 27. The method of claim 26, wherein said estradiol metabolite is selected from the group consisting of 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol and 4-hydroxyestradiol.
- 28. The method of claim 26, wherein said composition comprises a controlled release formulation of said composition.
- 29. The method of claim 26, wherein said composition comprises a prodrug of said estradiol metabolite.
- 30. A method for the prevention or treatment of hyperlipidemia in an individual, comprising:
administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.
- 31. The method of claim 30, wherein said estradiol metabolite is selected from the group consisting of 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol and 4-hydroxyestradiol.
- 32. The method of claim 30, wherein said composition comprises a controlled release formulation of said composition.
- 33. The method of claim 30, wherein said composition comprises a prodrug of said estradiol metabolite.
- 34. The method of claim 30, wherein said hyperlipidemia is hypercholesterolemia.
- 35. A method for the prevention or treatment of hypertension in an individual, comprising:
administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.
- 36. The method of claim 35, wherein said estradiol metabolite is selected from the group consisting of 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol and 4-hydroxyestradiol.
- 37. The method of claim 35, wherein said composition comprises a controlled release formulation of said composition.
- 38. The method of claim 35, wherein said composition comprises a prodrug of said estradiol metabolite.
- 39. A method for the prevention or treatment of diabetic nephropathy in an individual, comprising:
administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.
- 40. The method of claim 39, wherein said estradiol metabolite is selected from the group consisting of 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol and 4-hydroxyestradiol.
- 41. The method of claim 39, wherein said composition comprises a controlled release formulation of said composition.
- 42. The method of claim 39, wherein said composition comprises a prodrug of said estradiol metabolite.
- 43. A method for the prevention or treatment of proteinuria in an individual, comprising:
administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.
- 44. The method of claim 43, wherein said estradiol metabolite is selected from the group consisting of 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol and 4-hydroxyestradiol.
- 45. The method of claim 43, wherein said composition comprises a controlled release formulation of said composition.
- 46. The method of claim 43, wherein said composition comprises a prodrug of said estradiol metabolite.
- 47. A method for the purpose of controlling glucose levels in an individual, comprising:
administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.
- 48. The method of claim 47, wherein said estradiol metabolite is selected from the group consisting of 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol and 4-hydroxyestradiol.
- 49. The method of claim 47, wherein said composition comprises a controlled release formulation of said composition.
- 50. The method of claim 47, wherein said composition comprises a prodrug of said estradiol metabolite.
- 51. The method of claim 47, wherein said estradiol metabolite decreases polyuria in said individual.
- 52. The method of claim 47, wherein said estradiol metabolite decreases polydipsia in said individual.
- 53. The method of claim 47, wherein said estradiol metabolite decreases glycated hemoglobin levels in said individual.
- 54. The method of claim 47, wherein said estradiol metabolite improves oral glucose tolerance in said individual.
- 55. The method of claim 47, wherein said estradiol metabolite decreases glucosuria in said individual.
- 56. A method for reducing leptin levels in an individual, comprising:
administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.
- 57. The method of claim 56, wherein said estradiol metabolite is selected from the group consisting of 2-methoxyestradiol, 4-methoxy estradiol, 2-hydroxyestradiol and 4-hydroxy estradiol.
- 58. The method of claim 56, wherein said composition comprises a controlled release formulation of said composition.
- 59. The method of claim 56, wherein said composition comprises a prodrug of said estradiol metabolite.
RELATED APPLICATIONS
[0001] This application claims priority from U.S. Provisional Application No. 60/312,741 filed Aug. 17, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60312741 |
Aug 2001 |
US |